Topics:
Breast Cancer • Medical Oncology
How are you planning to use Mammaprint for the management of locally advanced ER+ breast cancer at clinical high risk of recurrence based on size and up to 3 lymph nodes?
The results of the 70 gene panel Mammaprint in combination with Adjuvant! Online were published in NEJM recently. How will you incorporate this data into clinical practice?
Answer from: Medical Oncologist at Academic Institution
This is an interesting question. I am going to use Mammaprint in the adjuvant setting for patients with high risk of recurrence for tumors of any size and for 0-3 LN positive. These were the criteria used in the MINDACT study, and the 5 year distant DFS in these patients was 95% with endocrine thera...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I agree with @Adam Brufsky in principle, although I am still cautious in younger women, and more disease in the lymph node. I have not used it in HER2+ disease either, but I agree that there is a small proportion of ER+HER2+ patients where chemotherapy may not as beneficial. I ...